Promus Capital’s AbbVie ABBV Stock Holding History

Promus Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$38.9K	Hold	168	–	–	0.02%	179
2025 Q2	$31.2K	Hold	168	–	–	0.02%	196
2025 Q1	$35.2K	Hold	168	–	–	0.03%	179
2024 Q4	$29.9K	Buy	+168	New	+$30.9K	0.02%	191

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Promus Capital's ABBV Position: Q3 2025 in Review

Promus Capital held its AbbVie (ABBV) position steady in Q3 2025 at 168 shares worth $38.9K. The position accounts for 0.02% of the portfolio, ranked #179.

Promus Capital first reported a position in ABBV in Q4 2024 and has held it in 4 quarters since. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Promus Capital held 168 shares of AbbVie worth $38.9K as of Q3 2025.
Promus Capital left its AbbVie share count unchanged in Q3 2025.
AbbVie made up 0.02% of Promus Capital's portfolio in Q3 2025, its #179 holding.
Promus Capital first reported a position in AbbVie in Q4 2024 and has held it in 4 quarters since.
3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Promus Capital's 13F filing for Q3 2025, filed 13 Nov 2025.